Literature DB >> 8641973

A human/mouse chimeric monoclonal antibody against intercellular adhesion molecule-1 for tumor radioimmunoimaging.

M Yamamura1, Y Hinoda, S Sasaki, M Tsujisaki, N Oriuchi, K Endo, K Imai.   

Abstract

A mouse-human chimeric antibody for intercellular adhesion molecule-1 (ICAM-1) was established by using heavy chain loss mouse mutant hybridoma and human immunoglobulin expression vector. The HA58 hybridoma secreted anti-ICAM-1 monoclonal antibody (MoAb) (IgG1, kappa). The gene of the mouse variable region of heavy chain was amplified and cloned by the polymerase chain reaction technique directly from the HA58 hybridoma RNA. The variable region of heavy chain was joined with an expression vector which contains human gamma 1 constant gene. The expression vector was transfected into heavy chain loss mutant cells HA58-7, which produced only murine immunoglobulin light chains. The resultant chimeric MoAb HA58, chHA58, retained full-binding reactivity to ICAM-1 compared with murine HA58 parental antibody. The chimeric MoAb chHA58 showed little antibody dependent cell-mediated cytotoxic activity against cultured tumor cells. Biodistribution studies with 99mTc-labeled chHA58 in nude mice bearing human gastric carcinoma JRST cells demonstrated that the tumor-blood ratio was 1.55 at 18 h after injection, when the tumors were clearly visible in gamma scintigraphy. These data suggest that chHA58 may be of practical use for radioimmunoimaging of a wide variety of tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641973      PMCID: PMC5921110          DOI: 10.1111/j.1349-7006.1996.tb00237.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  34 in total

1.  Technetium-99m-labeled anti-fibrin monoclonal antibody accumulation in an inflammatory focus.

Authors:  T Hirano; K Tomiyoshi; N Watanabe; M Tateno; N Oriuch; T Inoue; K Endo
Journal:  J Nucl Med       Date:  1992-06       Impact factor: 10.057

2.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

3.  Reduction-mediated technetium-99m labeling of monoclonal antibodies.

Authors:  S J Mather; D Ellison
Journal:  J Nucl Med       Date:  1990-05       Impact factor: 10.057

4.  Production of murine V-human Cr1 chimeric anti-TAG72 antibody using V region cDNA amplified by PCR.

Authors:  J H Xiang; J Roder; N Hozumi
Journal:  Mol Immunol       Date:  1990-08       Impact factor: 4.407

5.  CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1.

Authors:  Y Rosenstein; J K Park; W C Hahn; F S Rosen; B E Bierer; S J Burakoff
Journal:  Nature       Date:  1991-11-21       Impact factor: 49.962

6.  Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A.

Authors:  L K Sun; P Curtis; E Rakowicz-Szulczynska; J Ghrayeb; N Chang; S L Morrison; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

7.  Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation.

Authors:  H Potter; L Weir; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

8.  Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: role of ICAM-1 defined by antibody blocking and gene transfer.

Authors:  N Jonjic; S Alberti; S Bernasconi; G Peri; P Jílek; A Anichini; G Parmiani; A Mantovani
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

9.  T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis.

Authors:  A Anichini; R Mortarini; S Alberti; A Mantovani; G Parmiani
Journal:  Int J Cancer       Date:  1993-04-01       Impact factor: 7.396

10.  Establishment and characterization of mouse-human chimeric monoclonal antibody to erbB-2 product.

Authors:  T Ishida; M Tsujisaki; Y Hinoda; K Imai; A Yachi
Journal:  Jpn J Cancer Res       Date:  1994-02
View more
  1 in total

1.  Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody.

Authors:  S Sasaki; M Tsujisaki; T Jinnohara; T Ishida; M Sekiya; M Adachi; S Takahashi; Y Hinoda; K Imai
Journal:  Jpn J Cancer Res       Date:  1998-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.